FIORINAL CAPSULE

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

BUTALBITAL; CAFFEINE; ACETYLSALICYLIC ACID

から入手可能:

ARALEZ PHARMACEUTICALS CANADA INC

ATCコード:

N02BA71

INN（国際名）:

ACETYLSALICYLIC ACID, COMB WITH PSYCHOLEPTICS

投薬量:

50MG; 40MG; 330MG

医薬品形態:

CAPSULE

構図:

BUTALBITAL 50MG; CAFFEINE 40MG; ACETYLSALICYLIC ACID 330MG

投与経路:

ORAL

パッケージ内のユニット:

100

処方タイプ:

Schedule G (CDSA IV)

治療領域:

BARBITURATES

製品概要:

Active ingredient group (AIG) number: 0301241001; AHFS:

認証ステータス:

APPROVED

承認日:

2015-12-01

製品の特徴

PRODUCT INFORMATION
FIORINAL
®
(acetylsalicylic acid-caffeine-butalbital)
Capsules
USP
Combination Analgesic
Aralez Pharmaceuticals Canada Inc.*
DATE OF REVISION:
6733 Mississauga Rd., Suite 800
June 7, 2023
Mississauga, Ontario
L5N 6J5
www.miravohealthcare.com
Submission Control No: 270273
*Doing business as (d/b/a) Miravo Healthcare
_ _
_ _
_Page 2 of 22_
PRODUCT INFORMATION
NAME OF DRUG
FIORINAL
®
(acetylsalicylic acid-caffeine-butalbital)
USP
THERAPEUTIC CLASSIFICATION
Combination Analgesic
ACTION AND CLINICAL PHARMACOLOGY
Pharmacologically, FIORINAL
®
(ASA-caffeine-butalbital) combines the analgesic properties of
acetylsalicylic acid (ASA) with the anxiolytic and muscle relaxant
properties of butalbital.
PHARMACOKINETICS:
The behaviour of the individual components is described below.
_ACETYLSALICYLIC ACID (ASA) _
ASA
is
a
salicylate
that
binds
to
the
cyclooxygenase
enzyme
leading
to
a
reduction
in
prostaglandin activity. The systemic availability of ASA after an oral
dose is highly dependent
on the dosage form, the presence of food, the gastric emptying time,
gastric pH, antacids,
buffering agents, and particle size. These factors affect not
necessarily the extent of absorption of
total salicylates but more the stability of ASA prior to absorption.
During the absorption process and after absorption, ASA is mainly
hydrolyzed to salicylic acid
and distributed to all body tissues and fluids, including fetal
tissues, breast milk, and the central
nervous system (CNS). Highest concentrations are found in plasma,
liver, renal cortex, heart, and
lung. In plasma, about 50% - 80% of the salicylic acid and its
metabolites are loosely bound to
plasma proteins.
_ _
_ _
_Page 3 of 22_
The clearance of total salicylates is subject to saturable kinetics;
however, first-order elimination
kinetics are still a good approximation for doses up to 650 mg. The
plasma half-life for ASA is
about 12 minutes and for salicylic acid and/or total salicylates is
about 3 hours.
The elimination of therapeutic doses is through the kidneys